A Phase 2 Study to Evaluate the Safety and Efficacy of Pacritinib in Relapsed or Refractory Waldenström Macroglobulinemia
- Status
- RECRUITING
- Phase
- PHASE2
Clinical Trials Related to Waldenström Macroglobulinemia
Related studies linked through entity extraction aliases.
Preliminary Assessment of [18F]BL40 in PET/CT Scans
- Status
- NOT_YET_RECRUITING
- Phase
- N/A
Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Zanubrutinib, Ixazomib and Dexamethasone in Patients With Treatment Naive Waldenstrom's Macroglobulinemia
- Status
- COMPLETED
- Phase
- PHASE2
A Single-Arm, Expanded Access Study of Zanubrutinib in Participants With B-cell Malignancies
- Status
- NO_LONGER_AVAILABLE
- Phase
- N/A
A Study of Daratumumab in Patients With Relapsed or Refractory Waldenström Macroglobulinemia
- Status
- COMPLETED
- Phase
- PHASE2
BI-1206 and an Anti-CD20 Antibody in Patients With CD32b Positive B-cell Lymphoma or Leukaemia
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Comparison of ASCT and Conventional Chemotherapy in High Risk Waldenström Macroglobulinemia
- Status
- COMPLETED
- Phase
- PHASE4
The Comparison of RCD Versus BCD in Newly Diagnosed Waldenström Macroglobulinemia
- Status
- COMPLETED
- Phase
- PHASE4
The Efficacy of TCD Following by TP Maintenance Therapy in Newly Diagnosed WM
- Status
- COMPLETED
- Phase
- PHASE4
Expression of Ku70/XRCC6 in Waldenström's Macroglobulinemia
- Status
- COMPLETED
- Phase
- NA
ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma
- Status
- WITHDRAWN
- Phase
- PHASE1/PHASE2
Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
- Status
- TERMINATED
- Phase
- PHASE1
Study of BKM120 & Rituximab in Patients With Relapsed or Refractory Indolent B-Cell Lymphoma
- Status
- COMPLETED
- Phase
- PHASE1
Bortezomib and Filgrastim to Promote Stem Cell Mobilization in Patients With Non-Hodgkin Lymphoma or Multiple Myeloma
- Status
- COMPLETED
- Phase
- NA
Dose Monitoring of Busulfan and Combination Chemotherapy in Hodgkin or Non-Hodgkin Lymphoma Undergoing Stem Cell Transplant
- Status
- COMPLETED
- Phase
- EARLY_PHASE1
Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies
- Status
- COMPLETED
- Phase
- PHASE2